IDT Biologika
Dedicated to Contract Development and Manufacturing of
Viral Vaccines, Viral Vectors and Biologics

Learn how IDT Biologika is responding to the COVID-19 outbreak

Contract Development and Manufacturing of Viral Vaccines, Viral Vectors and Biologics

IDT Biologika specializes in the contract development and manufacturing of Viral Vaccines, Gene and Immunotherapeutics as well as sterile liquids and lyophilized Biologics. We help biopharmaceutical and biotech companies as well as the US government as part of research consortia with the challenging and complex process of translating viral vaccines and biopharmaceuticals from the research lab through clinical development to large-scale commercial manufacturing inculding drug substance production, fill & finish, packaging and analytics. IDT Biologika provides fully integrated services for GMP compliant end-to-end services in BSL2 facilites meeting EMA, FDA and ANVISA standards.

We strive for strong, trusting and enduring customer partnerships. Our almost 100 year tradition in manufacturing vaccines and biopharmaceuticals motivates and obligates us to advance our clients’ products to prevent and treat diseases that impact the health of people worldwide.

Latest IDT News

Positive interim summary of strategic realignment at CPhl trade fair:

Tuesday, 5. November 2019

IDT Biologika expands portfolio of viral vaccines and biologics more info

IDT Biologika Awarded new Task Order to Manufacture Vaccines and Biologics for Infectious Diseases

Monday, 4. November 2019

IDT Biologika Awarded new Task Order in the Scope of 10-Year NIH Contract to Manufacture Vaccines and Biologics for Infectious Diseases more info

IDT Biologika inaugurates new multifunctional production facility for vaccines at BioPharmaPark area

Friday, 5. July 2019

New building for vaccine production enables even more flexible reaction to customer demands more info

Ceva completes acquisition

Wednesday, 3. July 2019

Ceva completes acquisition of IDT veterinary business assets, moving closer to its 2020 objective of 50:50 bio-pharma split more info

IDT Biologika to concentrate on human vaccines and pharmaceuticals

Wednesday, 5. June 2019

Divestment of animal health business unit enables focus on global growth market more info

Twitter
@IDT Biologika

Wednesday, 1. April 2020

We are making every effort to protect our employees and to ensure the manufacturing of our clients‘ vital #vaccines… https://t.co/z3O91MQYIs more info

Monday, 9. March 2020

IDT is recognized as a winner of three CMO Leadership Awards across the categories capabilities, compatibility and… https://t.co/HSFMd87yBM more info

Friday, 14. February 2020

We are proud to be awarded a silver medal for #sustainability management once again! Following the silver medal in… https://t.co/oWTvlliMtW more info

Thursday, 6. February 2020

.@VWGroup and IDT Biologika celebrated the first e-crafter in Saxony-Anhalt and are now moving into the future as p… https://t.co/J8IZSg5cDy more info

Thursday, 30. January 2020

Join us at #DCATWeek2020 next month in #NYC. March 24-26, 2020, Meeting Suite 1206, Hotel New York Marriot East Sid… https://t.co/XME2wKPv0S more info

Thursday, 7. November 2019

IDT Biologika expands portfolio of viral #vaccines and #biologics https://t.co/TMKuYudaND #cphifrankfurt more info

Wednesday, 6. November 2019

RT @MDTechCouncil: Congratulations to #MTCMember: @idtbiologika Awarded New Task Order in the Scope of 10-Year NIH Contract to Manufacture… more info

Wednesday, 6. November 2019

"This major order from the NIAID is another important step in implementing our strategy," CEO Dr. Jürgen Betzing sa… https://t.co/yjdmODq2kA more info

Tuesday, 5. November 2019

IDT Biologika awarded new task order in the scope of 10-Year NIH contract to manufacture #vaccines and #biologics f… https://t.co/WxZNnmdJQY more info